Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CHPA files comments to FDA regarding OTC monograph system
CHPA’s comments underscored its support for the FDA’s re-examination of the system in an effort to complete the OTC Drug Review. CHPA believes this can best be accomplished
CHPA’s comments underscored its support for the FDA’s re-examination of the system in an effort to complete the OTC Drug Review. CHPA believes this can best be accomplished
The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled US clinical trials being conducted to evaluate NX-1207 2.5mg for the treatment of benign prostatic
The results published in the latest issue of the New England Journal of Medicine (NEJM) show that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow
This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss. DS Healthcare
In the suit, Acura alleges that a generic of Acura’s AVERSION oxycodone product, previously marketed by Pfizer under its brand name OXECTA, for which Ranbaxy is seeking approval
This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to the wider efforts of Johnson & Johnson
Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib
The company announced the issuance of US Patent No. 8,701,658 entitled ‘Ventilation Circuit Adaptor and Proximal Aerosol Delivery System’ which provides coverage for our novel disposable aerosol airway
Used for years to treat allergic asthma, the drug has been tested for the treatment of chronic hives with overwhelmingly positive results. For those that suffer from chronic
The patent covers Can-Fite’s drug, CF102 in the treatment of the liver function following liver resection (surgery) by helping the liver to regenerate and repair itself. In preclinical